Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin Liposome vs Epirubicin in HER2+ Early Breast Cancer (METIS)
NCT04172259Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2019
- Primary completion
- Sep 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegylated liposomal doxorubicin in breast cancer (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Pathological Complete Response rate. Started Jan 2019; status: active, not recruiting.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04172259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04172259.